Abstract
A class of new glycan-reactive broadly neutralizing antibodies represented by PGT121, 10-1074, and PGT128 has recently been discovered that targets specific N-glycans and the peptide region around the V3 domain. However, the glycan specificity and fine epitopes of these bNAbs remain to be further defined. We report here a systematic chemoenzymatic synthesis of homogeneous V3 glycopeptides derived from the HIV-1 JR-FL strain carrying defined N-glycans at N332, N301, and N295 sites. Antibody binding studies revealed that both the nature and site of glycosylation in the context of the V3 domain were critical for high-affinity binding. It was found that antibody PGT128 exhibited specificity for high-mannose N-glycan with glycosylation site promiscuity, PGT121 showed binding specificity for glycopeptide carrying a sialylated N-glycan at N301 site, and 10-1074 was specific for glycopeptide carrying a high-mannose N-glycan at N332 site. The synthesis and binding studies permit a detailed assessment of the glycan specificity and the requirement of peptide in the context of antibody-antigen recognition. The identified glycopeptides can be used as potential templates for HIV vaccine design.
Original language | English (US) |
---|---|
Pages (from-to) | 1566-1575 |
Number of pages | 10 |
Journal | ACS Chemical Biology |
Volume | 12 |
Issue number | 6 |
DOIs | |
State | Published - Jun 16 2017 |
Externally published | Yes |
Bibliographical note
Funding Information:We thank members of the Wang lab for technical assistance and discussions. We also thank P. Bjorkman and her lab members for kindly providing PGT128, 10-1074 and corresponding Fab proteins. This work was supported by the National Institutes of Health (NIH grants R01AI113896).
Publisher Copyright:
© 2017 American Chemical Society.